A PROSPECTIVE, RANDOMIZED, CONTROLLED STUDY TO EVALUATE DEVICE EFFICACY BETWEEN THE
HELIXAR ELECTROSURGICAL GENERATOR (HEG) VS. CONVENTIONAL ELECTROSURGICAL COAGULATION
(CEC) FOR CUTTING AND/OR COAGULATION OF TISSUE DURING MASTECTOMY PROCEDURES
Additional locations may be listed on ClinicalTrials.gov for NCT04165525.
See trial information on ClinicalTrials.gov for a list of participating sites.
The objective of this study is to evaluate device efficacy between the HelixAR
Electrosurgical Generator (HEG) and Conventional Electrosurgical Coagulation (CEC)
Systems for cutting and/or coagulation of tissue during mastectomy procedures and
reconstructive surgery.
The study is designed and powered to demonstrate the superiority of the HEG to CEC in
relation to a key efficacy measure: post-mastectomy procedure time to hemostasis.
Secondary outcome measures include: infection, drain duration, total drain output, blood
loss, and device related adverse events. These outcomes will be evaluated in a controlled
population undergoing mastectomy procedures.
Trial PhaseNo phase specified
Trial Typetreatment
Lead OrganizationSurgiQuest, Inc.